Brainsway Ltd
BWAY21.780USD
+0.850+4.06%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
413.90MMarket Cap
66.07P/E TTM
More Details of Brainsway Ltd Company
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
Brainsway Ltd Info
Ticker SymbolBWAY
Company nameBrainsway Ltd
IPO dateDec 24, 2006
CEOLevy (Hadar)
Number of employees120
Security typeDepository Receipt
Fiscal year-endDec 24
Address16 Hartum Street Rad Tower, 14Th Floor
CityJERUSALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code9777516
Phone97225813140
Websitehttps://www.brainsway.com/
Ticker SymbolBWAY
IPO dateDec 24, 2006
CEOLevy (Hadar)
Company Executives of Brainsway Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. David Zacut, M.D.
Dr. David Zacut, M.D.
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Dr. Yiftach Roth
Dr. Yiftach Roth
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Avner Hagai
Mr. Avner Hagai
Independent Director
Independent Director
--
--
Ms. Eti Michal Mitrany Rayten
Ms. Eti Michal Mitrany Rayten
Independent Director
Independent Director
--
--
Ms. Karen Sarid
Ms. Karen Sarid
Independent Director
Independent Director
--
--
Mr. Yosef (Yossi) Ben Shalom
Mr. Yosef (Yossi) Ben Shalom
Independent Director
Independent Director
--
--
Prof. Abraham Zangen, Ph.D.
Prof. Abraham Zangen, Ph.D.
Director
Director
--
--
Mr. Hadar Levy
Mr. Hadar Levy
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Avner Lushi
Mr. Avner Lushi
Independent Director
Independent Director
--
--
Mr. Christopher Boyer
Mr. Christopher Boyer
Vice President - Global Marketing
Vice President - Global Marketing
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David Zacut, M.D.
Dr. David Zacut, M.D.
Vice Chairman of the Board
Vice Chairman of the Board
--
--
Dr. Yiftach Roth
Dr. Yiftach Roth
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Avner Hagai
Mr. Avner Hagai
Independent Director
Independent Director
--
--
Ms. Eti Michal Mitrany Rayten
Ms. Eti Michal Mitrany Rayten
Independent Director
Independent Director
--
--
Ms. Karen Sarid
Ms. Karen Sarid
Independent Director
Independent Director
--
--
Mr. Yosef (Yossi) Ben Shalom
Mr. Yosef (Yossi) Ben Shalom
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
33.23M
81.01%
Other
7.79M
18.99%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Feb 6
Updated: Fri, Feb 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Valor Equity Partners
13.55%
Masters Capital Management, L.L.C.
5.10%
Phoenix Financial Ltd
3.56%
Acadian Asset Management LLC
2.01%
Renaissance Technologies LLC
1.60%
Other
74.18%
Shareholders
Shareholders
Proportion
Valor Equity Partners
13.55%
Masters Capital Management, L.L.C.
5.10%
Phoenix Financial Ltd
3.56%
Acadian Asset Management LLC
2.01%
Renaissance Technologies LLC
1.60%
Other
74.18%
Shareholder Types
Shareholders
Proportion
Private Equity
13.55%
Hedge Fund
8.87%
Investment Advisor/Hedge Fund
5.51%
Holding Company
3.56%
Individual Investor
2.61%
Investment Advisor
2.39%
Research Firm
0.60%
Pension Fund
0.39%
Other
62.52%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
88
6.12M
32.49%
+574.50K
2025Q3
88
5.55M
33.48%
-311.50K
2025Q2
83
5.91M
35.34%
-236.75K
2025Q1
83
6.15M
42.61%
-1.89M
2024Q4
77
6.11M
51.89%
+361.76K
2024Q3
66
3.47M
47.08%
-305.23K
2024Q2
58
3.74M
45.72%
-98.64K
2024Q1
55
3.84M
47.96%
-4.14M
2023Q4
47
4.07M
46.76%
+344.36K
2023Q3
42
3.70M
47.28%
-85.73K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Valor Equity Partners
2.66M
13.57%
+553.73K
+26.32%
Oct 06, 2025
Masters Capital Management, L.L.C.
1.00M
5.11%
--
--
Sep 30, 2025
Phoenix Financial Ltd
697.26K
3.56%
+456.90K
+190.09%
Oct 18, 2024
Acadian Asset Management LLC
394.56K
2.01%
+60.29K
+18.04%
Sep 30, 2025
Renaissance Technologies LLC
313.16K
1.6%
+29.30K
+10.32%
Sep 30, 2025
Essex Investment Management Company, LLC
310.68K
1.59%
+9.74K
+3.24%
Sep 30, 2025
Shulkin (Jonathan K.)
268.25K
1.37%
--
--
Oct 06, 2025
Gracias (Antonio J)
243.50K
1.24%
--
--
Oct 06, 2025
Two Sigma Investments, LP
193.80K
0.99%
+21.21K
+12.29%
Sep 30, 2025
Cresset Asset Management, LLC
157.46K
0.8%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Israel Innovative Technology ETF
1.8%
ActivePassive International Equity ETF
0.04%
iShares Neuroscience and Healthcare ETF
0%
ARK Israel Innovative Technology ETF
Proportion1.8%
ActivePassive International Equity ETF
Proportion0.04%
iShares Neuroscience and Healthcare ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
